Abeona Therapeutics using CRISPR to treat Fanconi anemia, raises $8.5M
New York biotech Abeona Therapeutics is taking a CRISPR/Cas9 approach to treating a rare anemia - and just raised $8.5 million in equity to bring it a little closer to clinic.
abeona therapeutics